XenoPort, Glaxo end collaboration on restless legs syndrome drug – The West Australian

by admin on November 8, 2012

XenoPort, Glaxo end collaboration on restless legs syndrome drug
The West Australian
(Reuters) – XenoPort Inc said it agreed with its marketing partner GlaxoSmithKline to end their collaboration on Horizant, a drug to treat restless legs syndrome. Glaxo will return all rights to the drug to XenoPort by April 30 and buy $20 million
XenoPort and GlaxoSmithKline Mutually Agree to Terminate Their Collaboration The Herald | HeraldOnline.com

all 23 news articles »

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: